Skip to content

Clinical trials

Pulmonary Disease, Chronic Obstructive trials in Belgium

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pulmonary Disease, Chronic Obstructive Country / region: Belgium Clear all

201 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20022
20034
20043
20052
20064
200712
200815
20099
201015
201118
20129
201311
201418
201515
201610
20177
20183
201911
20204
20217
20225
20236
20241
20257
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed151
Unknown status20
Terminated11
Recruiting9
Active, not recruiting5
Not yet recruiting2
Withdrawn2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Boehringer Ingelheim29
KU Leuven25
GlaxoSmithKline19
Novartis Pharmaceuticals16
AstraZeneca14
Cliniques universitaires Saint-Luc- Université Catholique de Louvain9
Chiesi Farmaceutici S.p.A.7
Novartis7
University Hospital, Antwerp7
FLUIDDA nv5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pulmonary Disease, Chronic Obstructive201
Emphysema9
Lung Diseases7
Asthma5
Dyspnea4
Respiration Disorders4
Bronchitis, Chronic3
Hypertension, Pulmonary3
Lung Diseases, Obstructive3
Respiratory Tract Diseases3

Trials

Showing 26 to 50 of 201. Each trial links to its page on Pharma Observatory.

101 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.